Exchange: NASDAQ·Updated 03:26 PM EDT
News
all
press releases
Immunovant (IMVT) Q1 2027 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
More News
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.
Zacks
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.
Zacks
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data...
Yahoo! Finance: News
The Biotech Supercycle Is Here: Retatrutide, VERVE-102, NEO100, and More Set to Transform Medicine
Biotechnology investors are entering one of the most catalyst-heavy clinical cycles in years as a wave of Phase 2 and Phase 3 programs begins reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders. $LLY, $NVO, $NTHI, $BAC, $STT, $BCS, $IMVT, $SRPT, $MRNA, $CRSP
24-7 Market News
These Analysts Increase Their Forecasts On Immunovant After Q4 Results
Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjust price targets.read more...
Benzinga
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence despite a wider Q4 loss.
Zacks
IMVT Rockets 35% Despite Wider Loss As Arthritis Drug Shines In Study
Immunovant posted encouraging Phase 2 data for its rheumatoid arthritis therapy, even as fourth-quarter net loss came in wider than expected.
Stocktwits
Can a New Arthritis Drug Make Immunovant the Next Biotech Star?
Can a New Arthritis Drug Make Immunovant the Next Biotech Star...
Yahoo! Finance: News

Advertisement|Remove ads.